Joshua Cohen

For over a decade, Amylyx Pharmaceuticals (NASDAQ: AMLX) has advanced an audacious mission to usher in a new era of treating diseases with high unmet needs. Today, our team is developing therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact: post-bariatric hypoglycemia (PBH), congenital hyperinsulinism (HI), Wolfram syndrome, and amyotrophic lateral sclerosis (ALS). Amylyx has a leadership team tenured in rare disease and a demonstrated track record of successfully developing and commercializing a medicine and providing access to thousands of people – experience that we’re leveraging in the development of our Phase 3 asset avexitide. As our organization takes on new challenges, we are committed to advancing science and innovation for the broader industry to open new pathways and approaches to developing treatments. Amylyx’s clinical trial results in collaboration with leading experts have been published in several peer-reviewed medical journals, including the New England Journal of Medicine. We’re building an organization on an audacious pursuit to discover and develop novel therapies for serious and fatal diseases because the communities we serve have no time to wait.